On Tuesday, Shares of EQT Midstream Partners LP (NYSE:EQM), lost -6.17% to $71.49.
EQT Midstream Partners, LP (EQM), an EQT Corporation company, declared recently that it has priced an underwritten public offering of 5,650,000 common units representing limited partner interests. Total gross proceeds of the offering (before under writers discounts and commissions and estimated offering expenses) will be about $406 million. EQT Midstream Partners, LP (EQM) has granted the underwriters a 30-day option to purchase up to an additional 847,500 common units.
EQM intends to use the net proceeds from the offering, counting any net proceeds from the underwriters’ exercise of their option to purchase additional common units, if any, for general partnership purposes, counting to fund a portion of EQM’s anticipated transmission and gathering expansion in 2016.
EQT Midstream Partners, LP provides natural gas transmission, storage, and gathering services in southwestern Pennsylvania and northern West Virginia. It owns, operates, acquires, and develops midstream assets in the Appalachian Basin.
Shares of Baxter International Inc (NYSE:BAX), inclined 0.85% to $37.98, during its last trading session.
Baxter International, declared a regular quarterly dividend of $0.115 per Baxter common share. This cash dividend is payable on January 4, 2016 to shareholders of record as of December 4, 2015.
Baxter provides a broad portfolio of essential renal and hospital products, counting home, acute and in-center dialysis; sterile IV solutions; infusion systems and devices; parenteral nutrition; biosurgery products and anesthetics; and pharmacy automation, software and services. The company’s global footprint and the critical nature of its products and services play a key role in expanding access to healthcare in emerging and developed countries. Baxter’s employees worldwide are building upon the company’s rich heritage of medical breakthroughs to advance the next generation of healthcare innovations that enable patient care.
This release comprises forward-looking statements concerning Baxter’s dividend. The statements are based on assumptions about many important factors, counting the following, which could cause actual results to differ materially from those in the forward-looking statements: continued strength in the company’s financial position, counting cash flows; future decisions of the board of directors of the company to continue payments to shareholders in the form of a dividend on a quarterly or other basis relative to alternative uses of funds; and other risks identified in the company’s most recent filing on Form 10-K and other SEC filings, all of which are available on Baxter’s website. Baxter does not undertake to update its forward-looking statements.
Baxter International Inc., develops, manufactures, and markets products for people with hemophilia, immune disorders, infectious diseases, kidney disease, trauma, and other chronic and acute medical conditions. The company’s Bio Science segment processes recombinant and plasma-based proteins to treat hemophilia and other bleeding disorders; plasma-based therapies to treat immune deficiencies, alpha-1 antitrypsin deficiency, burns and shock, and other chronic and acute blood-related conditions; and bio surgery products.
Finally, Shares of CF Industries Holdings, Inc. (NYSE:CF), ended its last trade with -1.72% loss, and closed at $47.34.
CF Industries Holdings, declared the filing with the U.S. Securities and Exchange Commission of a registration statement on Form S-4 containing a preliminary proxy statement/shareholder circular/prospectus in connection with the projected combination of CF and the European, North American and Global Distribution businesses of OCI N.V. (Euronext: OCI). While this registration statement has not yet become effective and the information contained therein is subject to change, it provides important information about CF, OCI and the projected combination.
The registration statement containing the preliminary proxy statement/shareholders circular/prospectus was filed by the new holding company under which the businesses will combine (temporarily named Darwin Holdings Limited) and is available through the SEC’s website at www.sec.gov under the company name “Darwin Holdings Ltd.”
The projected combination remains subject to approval by the shareholders of CF and OCI, in addition to certain other regulatory approvals and customary closing conditions.
CF Industries Holdings, Inc. manufactures and distributes nitrogen fertilizers and other nitrogen products worldwide. The company’s principal nitrogen fertilizer products comprise ammonia, granular urea, and urea ammonium nitrate solution. Its other nitrogen products comprise ammonium nitrate, diesel exhaust fluid, urea liquor, and aqua ammonia.